Clinical Edge Journal Scan

Specific clinical features indicate more timely prediagnostic investigations or referral for CRC


 

Key clinical point: An increase in consultation rates for colorectal cancer (CRC)-relevant symptoms and abnormal blood test results in the 2-year prediagnosis period hint at early initiation of specific investigations or referrals, thereby accelerating the diagnosis and treatment in some patients with symptomatic CRC.

Major finding: The earliest clinical feature to show increased recording rate from the baseline was rectal bleeding, at 10 months before colon cancer diagnosis (95% CI 8.3-11.7) and 8 months before rectal cancer diagnosis (95% CI 6.1-9.9). The rate of abnormal blood measurements (low hemoglobin levels, high platelet counts, etc) recorded increased from 9 months prediagnosis.

Study details: Findings are from a retrospective study that analyzed linked primary care and cancer registry data of patients with colon (n = 5033) or rectal (2516) cancer.

Disclosures: This study was supported by the National Institute for Health Research School for Primary Care Research and linked to the CanTest Collaborative funded by Cancer Research UK. Four authors are a part of the CanTest Collaborative.

Source: Moullet M et al. Pre-diagnostic clinical features and blood tests in patients with colorectal cancer: a retrospective linked-data study. Br J Gen Pract. 2022; 72(721):e556-e563 (Jul 28). Doi: 10.3399/BJGP.2021.0563

Recommended Reading

Preoperative ghrelin levels predict weight reduction after subtotal gastrectomy for gastric cancer
MDedge Hematology and Oncology
Endoscopic resection and surgery perform comparably against early gastric cancer
MDedge Hematology and Oncology
Baseline albumin level may predict PD-1 blockade-induced hyperprogressive disease in advanced gastric cancer
MDedge Hematology and Oncology
Neoadjuvant chemotherapy for gastric cancer: Determining factors with a prognostic impact
MDedge Hematology and Oncology
RHOA expression linked with clinical features in gastric cancer
MDedge Hematology and Oncology
High-dose vitamin C prolongs the PFS of patients with RAS mutation
MDedge Hematology and Oncology
Locally advanced rectal cancer: mFOLFOXIRI chemotherapy reduces the need for radiotherapy
MDedge Hematology and Oncology
No increase in second cancer development after additive chemotherapy for colon cancer
MDedge Hematology and Oncology
First-line bevacizumab better than cetuximab/panitumumab in right-sided RAS WT mCRC
MDedge Hematology and Oncology
Increasing CRC incidence: Can chemopreventive agents come to the rescue?
MDedge Hematology and Oncology